Nuclear Receptors: Full Throttle

 描述(由申请人提供)：请求支持由Carol A.Lange、Jennifer K.Richer和Karen E.Knudsen组织的题为核受体：全节流的Keystone研讨会。会议将于2016年1月10日至15日在犹他州雪鸟举行。核受体(NRs)是一大类配体依赖的转录因子“感应器”，可识别多种脂溶激素、维生素和膳食脂肪。NRs协调对正常内稳态至关重要的遗传反应程序，是生殖、发育、新陈代谢和免疫功能所必需的。出于这个原因，30多年来，NRs一直被认为是治疗多种疾病的有希望的药物靶点，包括癌症、糖尿病和其他内分泌或代谢疾病、肥胖、心血管疾病、高血压、炎症和胆汁淤积。对NRS的研究已经导致了许多针对致命疾病的成功疗法，这些疗法提高了寿命和生活质量。然而，仍然存在重大障碍，需要进一步详细了解 由NRS调控的主要基因调控网络，这些网络相对于疾病前和疾病状态在正常情况下有何不同，以及与靶向组织特异性效应(以减少副作用)和规避耐药机制相关的复杂问题。因此，进一步深入了解NR的全部功能以及与协同调节分子和信号通路的相互作用，对于将NRS用于健康和疾病以及开发下一代治疗方法是必要的。本次会议将汇聚我们众多的顶尖科学家，包括来自学术、临床和制药领域的高级和初级研究人员及其实习生，展示最新科学，突出创新和新兴技术的使用，探索新的方向，并在令人兴奋的天然生物领域开展合作和协同努力。

 DESCRIPTION (provided by applicant): Support is requested for a Keystone Symposia meeting entitled Nuclear Receptors: Full Throttle, organized by Carol A. Lange, Jennifer K. Richer and Karen E. Knudsen. The meeting will be held in Snowbird, Utah from January 10-15, 2016. Nuclear receptors (NRs) represent a large superfamily of ligand-dependent transcription factor "sensors" for a diverse set of fat-soluble hormones, vitamins and dietary lipids. NRs orchestrate genetic response programs critical for normal homeostasis, and are required for reproduction, development, metabolism and immune function. For this reason, NRs have been investigated for over 30 years as promising targets for drugs to treat a broad spectrum of diseases including cancer, diabetes and other endocrine or metabolic disorders, obesity, cardiovascular disease, hypertension, inflammation and cholestasis. Research on NRs has led to numerous successful therapies for deadly diseases that have improved both longevity and quality of life. However, significant hurdles remain that involve further detailed understanding of the major gene regulatory networks regulated by NRs, how these differ in normal relative to pre-disease and disease states, and the complex problems associated with targeting tissue-specific effects (to reduce side effects) and circumventing mechanisms of resistance. Thus, further insight into the full range of NR functions and interactions with co-regulatory molecules and signaling pathways is necessary for combinatorial approaches involving NRs in health and disease, and development of next-generation therapies. This meeting will bring together a diverse array of our leading scientists, including senior and junior investigators and their trainees, from academic, clinical and pharmaceutical settings, to showcase the latest science, highlight the use of innovative and emerging technologies, explore new directions, and develop collaborative and synergistic efforts in the exciting field of NR biology.